Olivia C./LinkedIn
Mar 26, 2026, 17:14
Olivia C.: Pfizer’s mRNA BNT162b2 Vaccine Does Not Induce High Levels of Inflammation
Olivia C., Business Development Manager at Pfizer, shared a post on LinkedIn:
“Precise data on changes in hematological parameters in vaccinated patients are essential to accurately reflect advancements in medical technology.
Infections can cause significant changes in certain hematological parameters and exacerbate inflammatory responses, such as the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and ferritin levels.
In contrast, Pfizer’s mRNA-based BNT162b2 vaccine does not induce high levels of inflammation.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop
-
Nov 17, 2026, 10:30Cheng-Hock Toh: Haematology Is Everywhere – But Is It Recognised?
-
Nov 17, 2026, 10:23Akshat Jain: The Importance of Knowing Your Sickle Cell Status
-
Nov 17, 2026, 10:12Caitlin Raymond: What Does Apheresis Really Cost?
-
Nov 17, 2026, 05:47Multidisciplinary Teams Kick Off SAHF MASAC ES 2026 with Pre-Symposium Workshops – South African Haemophilia Foundation
-
Nov 17, 2026, 05:41Boitumelo Malatji: South African Delegation Advances Advocacy Strategies at NNHF Southern Africa Workshop
-
Nov 17, 2026, 05:36Joining the PACTA Uganda Mental Health and Addiction Community Camp 2026 – Tackle Sickle Cell Africa
-
Nov 17, 2026, 05:30Nathan Connell: Women’s Hematology Summit 2027 to Address Hematologic Health Across the Lifespan
-
Nov 17, 2026, 05:25Mane Kurghinyan: Representing Armenia and HemAI Dynamics at the Falling Walls Lab Global Finale 2026